Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Receivables: 2015-2025

Historic Change in Receivables for Aytu Biopharma (AYTU) over the last 11 years, with Jun 2025 value amounting to $7.6 million.

  • Aytu Biopharma's Change in Receivables rose 533.05% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 238.22%. This contributed to the annual value of $7.6 million for FY2025, which is 246.68% up from last year.
  • Aytu Biopharma's Change in Receivables amounted to $7.6 million in FY2025, which was up 246.68% from -$5.2 million recorded in FY2024.
  • Aytu Biopharma's 5-year Change in Receivables high stood at $7.6 million for FY2025, and its period low was -$6.5 million during FY2022.
  • For the 3-year period, Aytu Biopharma's Change in Receivables averaged around $3.2 million, with its median value being $7.2 million (2023).
  • In the last 5 years, Aytu Biopharma's Change in Receivables plummeted by 323.12% in 2022 and then skyrocketed by 246.68% in 2025.
  • Yearly analysis of 5 years shows Aytu Biopharma's Change in Receivables stood at -$1.5 million in 2021, then slumped by 323.12% to -$6.5 million in 2022, then skyrocketed by 209.49% to $7.2 million in 2023, then crashed by 172.71% to -$5.2 million in 2024, then surged by 246.68% to $7.6 million in 2025.